Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimerʼs Disease
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 23 (4) , 293-307
- https://doi.org/10.2165/00023210-200923040-00003
Abstract
The mainstay of current management of patients with Alzheimer’s disease involves drugs that provide symptomatic therapy. Research approaches for future therapy of Alzheimer’s disease are focusing on...Keywords
This publication has 86 references indexed in Scilit:
- Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly SubjectsThe Journal of Clinical Pharmacology, 2008
- Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Memantine PharmacotherapyClinical Pharmacokinetics, 2007
- Global prevalence of dementia: a Delphi consensus studyPublished by Elsevier ,2006
- Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trialsInternational Journal of Geriatric Psychiatry, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Donepezil for dementia due to Alzheimer's diseasePublished by Wiley ,2003
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- GalantamineDrugs, 2000
- RivastigmineDrugs & Aging, 1998